![David C. Oxley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David C. Oxley
Direktor/Vorstandsmitglied bei TB Biosciences, Inc.
Aktive Positionen von David C. Oxley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TB Biosciences, Inc.
![]() TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA. | Direktor/Vorstandsmitglied | 01.08.2013 | - |
Karriereverlauf von David C. Oxley
Ehemalige bekannte Positionen von David C. Oxley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EXOPHARM | Präsident | 01.08.2021 | 01.01.2023 |
TRINITY BIOTECH PLC | Vertrieb & Marketing | - | - |
PLUS THERAPEUTICS, INC. | Vertrieb & Marketing | 21.05.2010 | - |
Statistik
International
Vereinigte Staaten | 3 |
Irland | 2 |
Australien | 2 |
Operativ
Sales & Marketing | 2 |
Director/Board Member | 1 |
President | 1 |
Sektoral
Health Technology | 4 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
PLUS THERAPEUTICS, INC. | Health Technology |
TRINITY BIOTECH PLC | Health Technology |
Private Unternehmen | 2 |
---|---|
TB Biosciences, Inc.
![]() TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA. | Health Services |
Exopharm Ltd.
![]() Exopharm Ltd. Pharmaceuticals: MajorHealth Technology Exopharm Ltd. engages in the research and development of biopharmaceutical drugs. The company was founded by Ian Dixon and Gregor Lichtfuss in 2013 and is headquartered in Camberwell, Australia. | Health Technology |
- Börse
- Insiders
- David C. Oxley
- Erfahrung